Form 4: CytomX Therapeutics Director Halley Gilbert Granted 38,000 Stock Options

CytomX Therapeutics, Inc. Director Halley E. Gilbert was granted 38,000 stock options with an exercise price of $2.82, vesting fully by the earlier of June 11, 2026, or the 2026 Annual Meeting.

Summary

• Halley E. Gilbert, a Director of CytomX Therapeutics, Inc. (CTMX), was granted 38,000 stock options.
• The options have an exercise price of $2.82 per share.
• The grant date for these options was June 11, 2025.
• The options are exercisable until June 10, 2035.
• The underlying shares subject to the option will vest 100% on the earlier of the first anniversary of the grant date (June 11, 2026) or the date of the 2026 Annual Meeting of the Issuer's stockholders, contingent on continuous service.

Sentiment

Score: 6

Explanation: The document reports a routine stock option grant to a director, which is a neutral to slightly positive event as it aligns director incentives with shareholder interests. It does not contain any significant positive or negative financial news.

Positives

• The grant of stock options to a director aligns their interests with shareholders, incentivizing long-term company performance.
• The options have a 10-year expiration period, providing a long window for potential value realization.

Negatives

• The options are not immediately exercisable and are subject to a vesting period, meaning the director does not yet have full ownership or control over the underlying shares.
• The value of the options is contingent on the future stock price exceeding the exercise price of $2.82.

Risks

• Stock Price Volatility: The value of the stock options is directly tied to the future market price of CytomX Therapeutics' common stock, which can fluctuate significantly.
• Vesting Conditions: The options are subject to vesting conditions, specifically continuous service as a director until the vesting date, meaning the options could be forfeited if service ceases prematurely.
• Dilution Risk: Upon exercise, these options will result in the issuance of new shares, potentially causing minor dilution for existing shareholders.

Future Outlook

The stock options granted to Director Halley E. Gilbert are set to vest 100% on the earlier of June 11, 2026, or the date of the 2026 Annual Meeting of stockholders, contingent on continuous service, aligning future incentives with company performance.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages. This practice aims to align the interests of leadership with those of shareholders by providing an incentive tied to the company's long-term stock performance.

Comparison to Industry Standards

• The grant of 38,000 stock options to a director is within the typical range for non-employee director compensation in the biotechnology sector, comparable to equity grants observed at similar-sized biopharmaceutical companies like Xencor (XNCR) or Zymeworks (ZYME), which often include a mix of stock options and restricted stock units.
• The 10-year expiration period for the options is standard for incentive stock options, providing ample time for the stock price to appreciate.
• The vesting schedule, tied to either a one-year anniversary or the next annual meeting, is also a common structure designed to ensure continued service and commitment from board members.

Related Party Transactions

• The grant of stock options to Halley E. Gilbert, a director of CytomX Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided to a member of the company's board of directors.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders by incentivizing stock price appreciation. However, future exercise of options could lead to minor dilution.
• Employees: No direct impact on general employees is indicated by this specific filing.
• Management: The transaction is part of the compensation structure for the board, which oversees management.

Next Steps

• The stock options will vest 100% on the earlier of June 11, 2026, or the date of the 2026 Annual Meeting of CytomX Therapeutics' stockholders, assuming continuous service.
• Following vesting, Halley E. Gilbert will have the right to exercise the options to purchase 38,000 shares of common stock at $2.82 per share until June 10, 2035.

Key Dates

Recommendation

Keywords

CytomX Therapeutics, CTMX, SEC Form 4, Stock Option Grant, Director Compensation, Halley E. Gilbert, Equity Compensation, Insider Transaction, Vesting Schedule